Evidence map›Paper›PMID 41301840›Full record

ReviewBiomedicines2025

Myocardial Fibrosis in Athletes: Risk Marker or Physiological Adaptation?

Vasiliki Katsi, Epameinondas Triantafyllou, Christos Fragoulis, Christos Vazaios, Spyridon Maragkoudakis, Alexandros Kasiakogias, Charalampos Vlachopoulos, Konstantinos P Tsioufis

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vasiliki KatsiFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.
Epameinondas TriantafyllouFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.
Christos FragoulisFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.ORCID 0000-0001-5598-9950
Christos VazaiosDepartment of Thoracic Surgery, General Oncological Hospital of Peiraeus, 18537 Pireas, Greece.ORCID 0009-0006-6917-2574
Spyridon MaragkoudakisGeneral Hospital of Chania Cardiology Department, 73300 Chania, Greece.
Alexandros KasiakogiasFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.ORCID 0000-0002-1090-4965
Charalampos VlachopoulosFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.ORCID 0000-0002-9904-3558
Konstantinos P TsioufisFirst Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.ORCID 0000-0002-7636-6725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endurance exercise is widely recognized for its cardiovascular benefits, including improved longevity and metabolic health. However, excessive endurance training may lead to adverse cardiac adaptations, such as myocardial fibrosis, detected via late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR). This review examines the dual role of myocardial fibrosis in athletes-as a potential risk marker for life-threatening arrhythmias or a benign byproduct of physiological remodeling. While moderate exercise promotes beneficial cardiac hypertrophy, ultra-endurance athletes exhibit a 10-20% increase in ventricular size and mass, alongside elevated cardiac biomarkers post-exercise. Myocardial fibrosis, particularly in the left ventricle (LV), is associated with arrhythmias and sudden cardiac death, especially when presenting as a subepicardial/midmyocardial patchy pattern. Studies report that 22% of athletes with this pattern experienced malignant arrhythmias, underscoring its clinical significance. Conversely, fibrosis may also reflect adaptive remodeling in some cases, complicating its interpretation. The mechanisms underlying fibrosis in athletes remain unclear but may involve repeated cardiac stress, inflammation, or distinct atherosclerotic plaque dynamics. CMR is critical for detecting fibrosis, though differentiating pathological from physiological patterns requires careful clinical correlation. Risk stratification must consider LGE patterns, arrhythmia history, and symptoms. Despite concerns, elite athletes generally exhibit increased longevity, highlighting the complex interplay between exercise benefits and risks. Further research is needed to clarify fibrosis mechanisms, refine diagnostic criteria, and guide management strategies to ensure athlete safety while preserving the advantages of endurance training.

Indexed as

athletescardiac magnetic resonanceexercisemyocardial fibrosisrisk stratificationventricular scar

Identifiers

PMID41301840
PMCPMC12650245

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.